• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Spectranetics to boost Stellarex spend

Spectranetics to boost Stellarex spend

April 24, 2015 By Brad Perriello

Spectranetics to boost Stellarex spend

Spectranetics (NSDQ:SPNC) yesterday said it plans to boost its research & development spend on the Stellarex drug-eluting balloon it acquired from Covidien early this year, aiming to expand its use into below-the-knee peripheral artery disease.

"Our team and global thought leaders believe the Stellarex DCB platform is ideally suited to treat BTK disease," president & CEO Scott Drake said in prepared remarks. "Accelerating this investment amplifies and elongates the impact of our powerful [drug-eluting balloon] program. Stellarex, in combination with our crossing solutions and laser atherectomy, establishes a comprehensive portfolio to treat peripheral artery disease generally and critical limb ischemia patients specifically."

The investment is expected to add $5 million to $6 million of product development, regulatory and clinical expense in 2015, the company said. A bid for an investigational device exemption from the FDA could lead to a U.S. clinical trial in mid-2016; Spectranetics said it hopes to win CE Mark approval in the European Union for the BTK indication during the 2nd half of next year.

Stellarex won CE Mark approval in the European Union last December, a month after Covidien announced the deal with Spectranetics. Covidien sold Stellarex for $30 million to appease anti-trust regulators ahead of its $50 billion merger with Medtronic (NYSE:MDT). The acquisition pushed Spectranetics much deeper into the red during the 1st quarter, the company said yesterday.

Spectranetics posted losses of -$27.3 million, or -65¢ per share, on sales of $57.4 million, widening losses by some 382.3% on 45.0% sales growth compared with Q1 2014. Adjusted to exclude 1-time items, losses per share were -30¢, missing Wall Street’s forecast by 7¢.

SPNC shares were down -24.6% to $26.15 apiece in mid-afternoon activity today.

Filed Under: MassDevice Earnings Roundup, News Well Tagged With: 2015, Covidien, Drug-Eluting Balloons, Q1, Spectranetics Corp.

More recent news

  • Imperative Care has positive stroke treatment study results
  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • Intuitive demonstrates remote telesurgery capabilities with da Vinci 5
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • CVRx announces Medicare win for Barostim therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy